Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy — Sponsor Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

7 Recruiting

9 Completed trials

5 Countries active

20 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 2 Phase II: 11 Phase I/II: 1 Phase IV: 1

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Adrenocortical carcinoma 2 Nicotine dependence 1 Prostate cancer 1 Adenoid cystic carcinoma of salivary gland 1 Laryngeal squamous cell carcinoma 1 Nasopharyngeal cancer recurrent 1 Pharyngeal cancer stage III 1 HER2 negative breast cancer 1 Pharyngeal cancer stage II 1 Squamous cell carcinoma of the oral cavity 1 Chronic kidney disease 1 Nasopharyngeal cancer 1

Top IMPs

CARBOPLATIN 2 LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN 2 PACLITAXEL 2 PEMBROLIZUMAB 2 ANNAMYCIN 1 AVELUMAB 1 AXITINIB 1 BALSTILIMAB 1 CLADRIBINE 1 CYTISINICLINE 1 EFTILAGIMOD ALFA 1 EMPAGLIFLOZIN 1

All trials

15 total

Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center,… Recruiting

2023-509235-39-00 Phase IV 1 country CYTISINICLINE; NICOTINE
177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregion… Recruiting

2023-504912-13-00 Phase II 1 country LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting

2022-500013-32-01 Phase III 3 countries
A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo… Recruiting

2023-504145-31-00 Phase II 1 country CARBOPLATIN; PACLITAXEL; PEMBROLIZUMAB; SODIUM CHLORIDE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to evaluate Efficacy and Safety of Empagliflozin in the prevention of Cardioto… Recruiting

2024-515495-13-00 Phase III 1 country EMPAGLIFLOZIN
Induction treatment of patients with head and neck squamous cell carcinoma using simultaneous chemotherapy and low-dose radiotherapy (iCHRTL… Recruiting

2024-517480-23-00 Phase II 1 country CARBOPLATIN; PACLITAXEL
Phase II study evaluating the efficacy of Nivolumab in the treatment of patients with nasopharyngeal cancer who progressed during or after p… Recruiting

2024-517479-19-00 Phase II 1 country NIVOLUMAB
Phase II study evaluating the efficacy and safety of preoperative immunotherapy (pembrolizumab with eftilagimod alfa) in combination with ra… Ended

2024-515971-37-00 Phase II 1 country EFTILAGIMOD ALFA; PEMBROLIZUMAB
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma Ended

2024-517205-82-00 Phase II 1 country
Assessment of tolerance and effectiveness of total body irradiation and cladribine before allogeneic hematopoietic cell transplantation in p… Ended

2024-517477-24-00 Phase II 1 country CLADRIBINE
A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-… Ended

2024-517380-22-00 Phase II 1 country BALSTILIMAB
Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended

2024-517389-40-00 Phase II 1 country
Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC) Ended

2024-517678-12-00 Phase I/II 1 country ANNAMYCIN
A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumo… Ended

2024-519176-95-00 Phase II 2 countries AVELUMAB; AXITINIB
The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) lab… Ended

2023-504699-73-00 Phase II 1 country LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN

Showing 1–15 of 15 trials

← All sponsors A–Z